4
Changes in Ownership
SAB Biotherapeutics, Inc. Filed Acc 0001062993-23-019668
Options or other derivatives
- Director acquired 16,269 shares (grant or award)
- Director acquired 16,269 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Sessa Capital (Master), L.P. Director | 2023-10-23 | Grant or award · Series A-1 Convertible Preferred Stock | +16,269 | $1,000.00 | $16,269,000 | 18,000 | D |
| Sessa Capital (Master), L.P. Director | 2023-10-23 | Option exercise · Tranche A Warrants | −16,269 | 0 | D | ||
Loading xslF345X05/form4.xml…